Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells. The main question it aims to answer is whether the combination of medicines can get rid of metastatic tumors in participants with non-castrate, recurrent, oligometastatic prostate cancer. Participants will undergo: * Treatment with pTVG-HP * Treatment with Nivolumab * Radiation Therapy

Trial Details

NCT ID

NCT07090148

Phase

PHASE1

Sponsor

University of Wisconsin, Madison

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

pTVG-HP DNA vaccine
Anti-PD-1 monoclonal antibody

Locations (sample)

Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

Participants must be at least 18 years of age with a histologic diagnosis of adenocarcinoma of the prostate
Participants must have undergone radical prostatectomy
Participants must have completed local therapy by surgery, and any adjuvant/salvage radiation therapy (if required), at least 3 months prior to ent…
Participants must have biochemically recurrent disease defined by the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →